Amylin release during oral glucose tolerance test

Diabetic Medicine

Volumn 14, Issue SUPPL. 2, 1997, Pages

  Thomaseth, K ^a,d   Pacini, G ^a   Clodi, M ^b   Kautzky Willer, A ^b   Nolan, J J ^c   Prager, R ^b   Olefsky, J M ^c   Ludvik, B ^b  

^a Inst of Syst Sci and Biomed Eng   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Istituto di Ingeneria Biomedica del CNR   (Italy)

Author keywords

Amylin; C peptide secretion; Insulin secretion; Mathematical modelling

Indexed keywords

AMYLIN; C PEPTIDE;

ARTICLE; CELL DEATH; DATA ANALYSIS; DIABETES MELLITUS; DRUG RELEASE; INSULIN RESISTANCE; LIVER METABOLISM; MATHEMATICAL MODEL; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL;

AMYLOID; C-PEPTIDE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 0030848147     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199706)14:2+3.0.CO;2-0     Document Type: Article

References (17)

1. Hartter E, Svoboda T, Ludvik B et al. Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia 1991; 34: 52-54.
2. Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide: a novel controversy in diabetes research. Diabetologia 1992; 35: 297-303.
3. Enoki S, Mitsukawa T, Takemura J, et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 97-102.
4. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-II diabetes mellitus. Nature 1994; 368: 756-760.
5. Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 1991; 40: 1615-1619.
6. Moyses C, Young A, Kolterman O. Modulation of gastric emptying is a therapeutic approach to glycaemic control. Diabet Med 1996; 13: S34-S38.
7. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin profiles are elevated in IGT subjects vs normal controls. Diabetes 1995; 44 (suppl 1): 238A.
8. Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. Integrated mathematical model to assess B-cell activity during the oral glucose test. Am J Physiol 1996; 270: E522-E531.
9. Ludvik B, Nolan JJ, Roberts A, et al. A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 1995; 95: 2232-2238.
10. de Boor C. A Practical Guide to Splines. New York: Springer, 1978.
11. Thomaseth K. PANSYM: a tool for mathematical modelling, analysis and control of metabolic and pharmacokinetic systems. Comp Meth Programs Biom 1994; 42: 99-112.
12. Kautzky-Willer A, Thomaseth K, Pacini G, et al. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994; 37: 188-194.
13. Kautzky-Willer A, Thomaseth K, Clodi M, et al. B-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 1996; 45: 486-491.
14. Polonsky K, Licinio-Paixao J, Given BD, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and Type I diabetic patients. J Clin Invest 1986; 77: 98-105.
15. Ferrannini E, Cobelli C. The kinetics of insulin in man. II. Role of the liver. Diabet Metab Rev 1987; 3: 365-397.
16. Kautzky-Willer A, Thomaseth K, Ludvik B, et al. Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes. Diabetes 1997; 46: 607-614.
17. Cobelli C, Pacini G. Insulin secretion and hepatic extraction in humans by minimal modeling of C-peptide and insulin kinetics. Diabetes 1988; 37:223-231.